Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, Michigan, United States of America.
PLoS One. 2011;6(11):e27486. doi: 10.1371/journal.pone.0027486. Epub 2011 Nov 16.
Acute megakaryocytic leukemia (AMkL) in Down syndrome (DS) children is uniformly associated with somatic GATA1 mutations, which result in the synthesis of a shorter protein (GATA1s) with altered transactivation activity compared to the wild-type GATA1. It is not fully established whether leukemogenesis and therapeutic responses in DS AMkL patients are due to loss of the wild-type GATA1 or due to a unique function of GATA1s.
Stable clones of CMK cells with decreased GATA1s or Bcl-2 levels were generated by using GATA1- or BCL-2-specific lentivirus shRNAs. In vitro ara-C, daunorubicin, and VP-16 cytotoxicities of the shRNA stable clones were determined by using the Cell Titer-blue reagent. Apoptosis and cell cycle distribution were determined by flow cytometry analysis. Changes in gene transcript levels were determined by gene expression microarray and/or real-time RT-PCR. Changes in protein levels were measured by Western blotting. In vivo binding of GATA1s to IL1A promoter was determined by chromatin immunoprecipitation assays.
Lentivirus shRNA knockdown of the GATA1 gene in the DS AMkL cell line, CMK (harbors a mutated GATA1 gene and only expresses GATA1s), resulting in lower GATA1s protein levels, promoted cell differentiation towards the megakaryocytic lineage and repressed cell proliferation. Increased basal apoptosis and sensitivities to ara-C, daunorubicin, and VP-16 accompanied by down-regulated Bcl-2 were also detected in the CMK GATA1 shRNA knockdown clones. Essentially the same results were obtained when Bcl-2 was knocked down with lentivirus shRNA in CMK cells. Besides Bcl-2, down-regulation of GATA1s also resulted in altered expression of genes (e.g., IL1A, PF4, and TUBB1) related to cell death, proliferation, and differentiation.
Our results suggest that GATA1s may facilitate leukemogenesis and potentially impact therapeutic responses in DS AMkL by promoting proliferation and survival, and by repressing megakaryocytic lineage differentiation, potentially by regulating expression of Bcl-2 protein and other relevant genes.
唐氏综合征(Down syndrome,DS)患儿的急性巨核细胞白血病(acute megakaryocytic leukemia,AMkL)普遍与体细胞 GATA1 突变相关,导致与野生型 GATA1 相比,合成较短的蛋白(GATA1s),其转录激活活性发生改变。尚未完全确定 DS AMkL 患者的白血病发生和治疗反应是由于野生型 GATA1 的缺失还是由于 GATA1s 的独特功能。
使用 GATA1 或 BCL-2 特异性慢病毒 shRNA 生成 CMK 细胞中 GATA1s 或 Bcl-2 水平降低的稳定克隆。通过 Cell Titer-blue 试剂测定 shRNA 稳定克隆对阿糖胞苷、柔红霉素和 VP-16 的体外细胞毒性。通过流式细胞术分析测定细胞凋亡和细胞周期分布。通过基因表达微阵列和/或实时 RT-PCR 测定基因转录水平的变化。通过 Western blot 测定蛋白质水平的变化。通过染色质免疫沉淀测定法测定 GATA1s 与 IL1A 启动子的体内结合。
慢病毒 shRNA 敲低 DS AMkL 细胞系 CMK(携带突变 GATA1 基因且仅表达 GATA1s)中的 GATA1 基因,导致 GATA1s 蛋白水平降低,促进向巨核细胞谱系分化并抑制细胞增殖。在 CMK GATA1 shRNA 敲低克隆中还检测到基础凋亡增加和对阿糖胞苷、柔红霉素和 VP-16 的敏感性增加,同时 Bcl-2 下调。当用慢病毒 shRNA 在 CMK 细胞中敲低 Bcl-2 时,得到了几乎相同的结果。除了 Bcl-2 之外,GATA1s 的下调还导致与细胞死亡、增殖和分化相关的基因(例如,IL1A、PF4 和 TUBB1)的表达发生改变。
我们的结果表明,GATA1s 通过促进增殖和存活,并通过抑制巨核细胞谱系分化,可能促进白血病的发生,并可能通过调节 Bcl-2 蛋白和其他相关基因的表达来影响 DS AMkL 的治疗反应。